Document is current
Any future updates will be listed below
-
Authors
Braun, Jürgen https://orcid.org/0000-0002-9156-5095
Kiltz, Uta https://orcid.org/0000-0001-5668-4497
Deodhar, Atul
Tomita, Tetsuya
Dougados, Maxime https://orcid.org/0000-0003-3009-6229
Bolce, Rebecca
Sandoval, David
Lin, Chen-Yen
Walsh, Jessica
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03129100 at ClinicalTrials.govnct03129100 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.4280
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS0930 SAFETY AND EFFICACY OF IXEKIZUMAB TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR CLINICAL TRIAL RESULTS FROM THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2022-eular.140
POS0912 LONG-TERM TREATMENT WITH IXEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: TWO-YEAR RESULTS FROM COAST-Y
https://doi.org/10.1136/annrheumdis-2021-eular.1124
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct02696785 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.4280
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS0930 SAFETY AND EFFICACY OF IXEKIZUMAB TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR CLINICAL TRIAL RESULTS FROM THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2022-eular.140
POS0912 LONG-TERM TREATMENT WITH IXEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: TWO-YEAR RESULTS FROM COAST-Y
https://doi.org/10.1136/annrheumdis-2021-eular.1124
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct02696798 at ClinicalTrials.govDocuments that mention this clinical trial
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1612
OP0046 EFFECT OF IXEKIZUMAB TREATMENT ON MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; A POST-HOC ANALYSIS OF A PLACEBO AND ACTIVE CONTROLLED RCT
https://doi.org/10.1136/annrheumdis-2024-eular.602
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
POS0901 IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.211
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.169
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
https://doi.org/10.1136/annrheumdis-2024-eular.623
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2024-004429
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
nct02757352 at ClinicalTrials.govDocuments that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
https://doi.org/10.1136/annrheumdis-2021-eular.1620
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials
https://doi.org/10.1007/s40744-025-00810-5
THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2053
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (Results)
https://doi.org/10.1136/annrheumdis-2019-216118
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1615
OP0238 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1613
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1466
FRI0420 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SF-36 RESULTS OF TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.1237
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0400 LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS/ANKYLOSING SPONDYLITIS: AN INTEGRATED ANALYSIS OF COAST-V AND COAST-W
https://doi.org/10.1136/annrheumdis-2019-eular.1232
POS0909 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS IN PATIENTS IRRESPECTIVE OF HLA-B27 STATUS: POOLED RESULTS FROM THE COAST-V AND COAST-W TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.801
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0908 EFFICACY OF IXEKIZUMAB THROUGH 52 WEEKS FOR IMPROVING PERIPHERAL JOINT INVOLVEMENT AMONG PATIENTS WITH RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.761
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
POS0915 SUSTAINABILITY OF IXEKIZUMAB RESPONSE AT THE INDIVIDUAL PATIENT LEVEL OVER TIME IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1340
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
AB0471 PATIENTS WITH RADIOGRAPHIC axSpA WHO PROGRESSED FROM ASAS20 AT WEEK 16 TO ASAS40 AT WEEK 52: RESULTS FROM COAST-W
https://doi.org/10.1136/annrheumdis-2021-eular.1823
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
FRI0421 IXEKIZUMAB SIGNIFICANTLY REDUCED PAIN, INFLAMMATION, AND FATIGUE IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLARTHRITIS (R-AXSPA)/ANKYLOSING SPONDYLITIS (AS)
https://doi.org/10.1136/annrheumdis-2019-eular.1236
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
Documents that mention this clinical trial
POS0926 NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.2079
THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS
https://doi.org/10.1136/annrheumdis-2020-eular.2027
THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS
https://doi.org/10.1136/annrheumdis-2020-eular.2056
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
https://doi.org/10.1136/annrheumdis-2020-219717
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2021-001839
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
https://doi.org/10.1136/rmdopen-2021-002165
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
https://doi.org/10.1136/annrheumdis-2023-eular.82
FRI0278 IXEKIZUMAB IMPROVES SELF-REPORTED OVERALL FUNCTIONING AND HEALTH AS MEASURED BY THE ASAS HEALTH INDEX IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS OF A PHASE 3 RANDOMIZED, ACTIVE AND PLACEBO-CONTROLLED TRIAL (COAST-X)
https://doi.org/10.1136/annrheumdis-2020-eular.1361
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
https://doi.org/10.1007/s12325-022-02132-2
POS0957 EXTERNAL VALIDATION OF THE ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN THREE PHASE-3 RCTs
https://doi.org/10.1136/annrheumdis-2022-eular.372
OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.164
POS0301 STRUCTURAL OUTCOMES IN THE SACROILIAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.2322
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration
https://doi.org/10.1007/s12325-025-03305-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
https://doi.org/10.1136/ard-2022-222731
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (Not applicable)
- License Information
